FSDV Sarreguemines【FAYE】銘柄情報 | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
ヨーロッパ
EU
FSDV Sarreguemines (FAYE) 銘柄情報

FSDV Sarreguemines (FAYE)

17.60

0.00

( 0.00% )

更新日時： 15:32:55

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

17.60

買値

17.30

売値

20.40

出来高

0.00

0.00 日の範囲 0.00

14.00 52 週間の範囲 21.40

時価総額

前日終値

17.60

始値

-

時刻

最終取引時間

-

財務取引量

-

VWAP

-

平均取引量 (3 か月)

0.00

発行済株式数

113,691

配当利回り

-

PER

-3.38

1 株当たり利益 (EPS)

-5.21

歳入

-

純利益

-592k

セクター

Platemakng, Related Services

業界

Platemakng, Related Services

ウェブサイト

www.fsdv.fr

本社

Paris, Paris, Fra

設立

-

FSDV Sarreguemines is listed in the Platemakng, Related Services sector of the ユーロネクスト with ticker FAYE. The last closing price for FSDV Sarreguemines was 17.60 €. Over the last year, FSDV Sarreguemines shares have traded in a share price range of 14.00 € to 21.40 €.

FSDV Sarreguemines currently has 113,691 shares in issue. The market capitalisation of FSDV Sarreguemines is 2.00 € million. FSDV Sarreguemines has a price to earnings ratio (PE ratio) of -3.38.

Étude d’un projet de cession de F.S.D.V.

Étude d’un projet de cession de F.S.D.V. COMMUNIQUÉ FINANCIER Paris, le 4 juillet 2019 Étude d’un projet de cession de F.S.D.V. Après avoir progressivement, entre 2003 et 2009, cédé les...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	17.6	17.6	17.6	0	0	DE
4	1.4	8.64197530864	16.2	17.6	16.2	1	17.6	DE
12	1.4	8.64197530864	16.2	17.6	16.2	0	17.6	DE
26	-3.8	-17.7570093458	21.4	21.4	16.2	49	16.2071588	DE
52	-2.4	-12	20	21.4	14	27	16.27787369	DE
156	-8.8	-33.3333333333	26.4	34.8	14	12	17.65320641	DE
260	-18.4	-51.1111111111	36	39.4	14	14	24.98301551	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
ALCYBCybergun	0.0002 € (100.00%)	3.71M
ATOAtos SE	0.2958 € (89.62%)	16.1M
ALIMOGroupimo	0.276 € (46.03%)	100
ALROCRoctool	0.368 € (26.03%)	124.7k
ALARFAdeunis	0.784 € (20.99%)	2.94k
BIDSGascogne DS	0.0024 € (-52.00%)	21.68k
ALMERSapmer	6.40 € (-14.67%)	2
ALBDMBD Multi-Media	1.14 € (-11.97%)	204
ALDEVDevernois Sa	10.30 € (-11.97%)	7
TVRBAction Televerbier	48.60 € (-11.64%)	2
BCPBanco Comercial Portugues SA	0.4485 € (0.88%)	25.11M
ATOAtos SE	0.2958 € (89.62%)	16.1M
ALTDTonner Drones	0.0106 € (6.00%)	11.49M
ALNEVNeovacs	0.0002 € (0.00%)	11.39M
ALHPIHopium SA	0.0094 € (-1.05%)	8.66M

baltimorebullet

baltimorebullet 3分前

How about a the acceptance of a peer-reviewed manuscript titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,”

NEW YORK – November 25, 2024
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasda

Checkmate 36

Checkmate 36 3分前

Marty,
Take a deep breath, think for a second, and don’t be so myopic.

If you are searching for hope for this company to succeed…..which one can assume that’s what your doing as you state, your a long, you need to take your “readers” off, take the blinders off, and really let

glenn1919

glenn1919 3分前

RGTI.....NVTS......https://stockcharts.com/h-sc/ui?s=NVTS&p=W&b=5&g=0&id=p84354014936

kaisdaboss88

kaisdaboss88 3分前

$DPUI tiny os history of making huge moves with a 600million OS this will run wild when volume comes in loading tickets here.

Guzzi62

Guzzi62 3分前

So all the posters thinking a peer review would never happen are likely keeping a low profile today.

I don't see any name mentioned regarding the journal, expect: medical journal with focus on Alzheimer’s disease.

Further in the press release: “We are on track for regu

tw0122

.58 flipping half from .47

kaisdaboss88

kaisdaboss88 4分前

$VNTH another low floater dilution free shell insiders own many shares solid loading opportunities

VoyagerRealm96

VoyagerRealm96 4分前

No.more shell risk on OTC 😍😍😍😍😍😍

glenn1919

glenn1919 5分前

QMCO....WLDS....MULN......................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936

kaisdaboss88

kaisdaboss88 5分前

$PRDL nice dilution free shell insiders own 700mill shares keep on your radar.

Hoskuld

Hoskuld 5分前

Simufilam did not meet endpoints: https://finance.yahoo.com/news/cassava-sciences-topline-phase-3-123000846.html

tw0122

.53 style="caret-color: rgb(0, 0, 0); color: rgba(0, 0, 0, 1); font-family: -apple-system; font-size: 15px"“We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated

BornAgain

BornAgain 6分前

$BWMG is the only profitable company that sells for .006!!!

Could this be a zip code changer!!! Do your own DD.

https://www.otcmarkets.com/filing/html?id=17989053&guid=F5Y-kqhAVXGaJth

cfoofme

cfoofme 7分前

The same IMMINENT news you posted 2-3 years ago. Please update us re which of those will occur between now and end of 2024. Thanks.

PonkenPlonken

PonkenPlonken 8分前

SAVA will be toast on open. Their cognitive improvement in Alzheimers is beaten by daily stretching and taking a walk in patients.
Atleast they canceled their other ph3 trial.... They have raised false hopes in too many patients already.
Question is will they face legal consequences fo

tw0122

.47 . - Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -

WilliamMunny

WilliamMunny 9分前

Goodbye Cassava

linkvest

linkvest 9分前

Doubt that is going to happen.... Hitting the 7s already this morning LOLOL>..

Risk vs Reward

Risk vs Reward 9分前

Magnum7419

Magnum7419 11分前

This is worth a repeat imho!!!!!!!!!!!!

Read earlier posts on RSS before you comment . There will be no RSS for 18-24 months. Only when we are ready and ""approved"" to uplist. There is no advantage for us over investors. When and if it happens it affects us as well.

Hoskuld

Hoskuld 11分前

tredenwater, OL trials are problematic in AD - we have seen that several times. I love the idea of a limited look and adjustment but not OL. I also really like Anavex's approach to trials - except for the size and number. FWIW, Anavex itself admits it screwed up - it was trying to do the bare min

Truthsocial

Truthsocial 11分前

https://www.prageru.com/video/dr-marty-makary-on-eye-opening-discoveries-in-health-and-medicine

New FDA COMMISSIONER SOON ENOUGH from JOHNS HOPKINS
help is arriving to clean out the skat
And the garbage finally

RDGL coming soon enough
MAYO CLINI

Shonnieville

Shonnieville 11分前

She'll risk removed on the otc profile!

Let's go!

Doc328

Doc328 11分前

“Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,” in a medical journal with focus on Alzheimer’s disease.

WTF, top tier I'm sure

tradernewstip

tradernewstip 12分前

$ILLR On alert!! Former Head of Product at TikTok Sean Kim joins Triller Group https://finance.yahoo.com/news/former-head-product-tiktok-sean-133000625.html

FSDV Sarreguemines

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約